NCT00955604CompletedNot Applicable
Investigation of the Occurrence of Serotonin Toxicity in Parkinson's Disease (PD) Patients Treated Concomitantly With Rasagiline and Antidepressants, Using Retrospective Chart Review
Teva Branded Pharmaceutical Products R&D, Inc.0 sites1,500 target enrollmentStarted: July 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 1,500
- Primary Endpoint
- The frequency of serotonin toxicity, as determined by the Adjudication Committee will be calculated for each Group. The primary comparison will be Group R+AD vs. Group R and vs. Group AD
Study Overview
Brief Summary
To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to PD patients receiving antidepressants, but not rasagiline.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female patients with a diagnosis of PD
- •Rasagiline treatment as mono- or adjunct therapy for PD with concomitant antidepressant medication (SSRIs, SNRIs, St. John's wort and/or TCAs) at any time during the specified review period, OR Rasagiline treatment as mono- or adjunct therapy for PD without concomitant antidepressant medication (SSRIs, SNRIs, St. John's wort and/or TCAs) at any time during the specified review period. OR Antidepressant therapy (SSRIs, SNRIs, St. John's wort and/or TCAs) and any other dopaminergic anti-PD treatment besides rasagiline or selegiline at any time during the specified review period
- •Willing to consent to review of office chart and to review of records of ER visits and/or hospitalizations corresponding to the review window, if required
- •Patients previously participating in a rasagiline clinical trial (and their follow-up protocols) are eligible, provided that they did not receive antidepressant therapy during trial participation.
- •In addition to the above criteria, each group has specific inclusion criteria stated below:
- •Group R+AD: Enrollment in this group requires that patients must have taken rasagiline and an antidepressant (SSRIs, SNRIs, St. John's wort and/or TCAs, regardless of indication) within 14 days of each other (or five weeks, if fluoxetine preceded rasagiline).
- •Group R: Enrollment in this group requires patients must have at least 2 months of rasagiline use.
- •Group AD: Patients must be taking an approved dopaminergic medication for PD. Enrollment in this group requires that patients must have at least 2 months of treatment with an antidepressant medication.
Exclusion Criteria
- •Use of rasagiline for any indication other than PD
- •Patients taking a monoamine oxidase inhibitor (MAOI) antidepressant and/or selegiline
- •Inability or unwillingness to request records of ER visits and/or hospitalizations corresponding to the review period.
Arms & Interventions
Group R
At least 2 months of rasagiline
Intervention: Group R Rasagiline (Drug)
Group AD
At least 2 months of Anti-PD and Rasagiline
Intervention: Group AD Anti-PD + Antidepressant (Drug)
Group R+AD
Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days
Intervention: Group R+AD Rasagiline + Antidepressant (Drug)
Outcomes
Primary Outcomes
The frequency of serotonin toxicity, as determined by the Adjudication Committee will be calculated for each Group. The primary comparison will be Group R+AD vs. Group R and vs. Group AD
Time Frame: 9 months
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Recruiting
Not Applicable
Serotonin Release in Premotor and Motor PDParkinson'sNeurodegenerative DiseasesNeurodegenerationPositron Emission TomographyParkinson's DiseaseParkinson DiseaseNCT05516732University of Exeter42
Completed
Phase 2
EMD 128130 for the Treatment of Parkinson's DiseaseParkinson's DiseaseNCT00009048National Institute of Neurological Disorders and Stroke (NINDS)30
Recruiting
Not Applicable
Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)Parkinson DiseaseNCT06008704University Hospital, Toulouse34
Completed
Not Applicable
Exploratory Study of the Expression of the Serotonergic 5-HT4 Receptor in Parkinson's DiseaseParkinson DiseaseNCT05916625Hospices Civils de Lyon40
Completed
Phase 2
ACP-103 to Treat Parkinson's DiseaseDyskinesiasParkinson's DiseaseNCT00086294National Institute of Neurological Disorders and Stroke (NINDS)40